今日の臨床サポート 今日の臨床サポート
関連論文:
img  2:  Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis.
 
著者: Kalpana Muthusamy, Mohamed B Elamin, Galina Smushkin, Mohammad Hassan Murad, Julianna F Lampropulos, Khalid B Elamin, Nisrin O Abu Elnour, Juan F Gallegos-Orozco, Mitra M Fatourechi, Neera Agrwal, Melanie A Lane, Felipe N Albuquerque, Patricia J Erwin, Victor M Montori
雑誌名: J Clin Endocrinol Metab. 2010 Sep;95(9):4161-72. doi: 10.1210/jc.2009-2616.
Abstract/Text CONTEXT: Treatment for patients with congenital adrenal hyperplasia (CAH) may affect the final height of these patients.
OBJECTIVE: Our objective was to determine the distribution of achieved height in patients with classic CAH diagnosed at infancy or early childhood and treated with glucocorticoids.
DATA SOURCES: We searched MEDLINE, EMBASE, Cochrane Library, ISI Web of Science, and Scopus through September 2008; the reference sections of included studies; and expert files.
STUDY SELECTION: Eligible studies included patients diagnosed with CAH before age 5 and followed to final height.
DATA EXTRACTION: Reviewers working in duplicate independently extracted data on study characteristics and outcomes and determined each study's risk of bias.
DATA SYNTHESIS: The sd score (SDS) for final height and corrected height (defined as final height SDS - midparental height SDS) were estimated from each study and pooled using random-effects metaanalysis. The I(2) statistic was used to assess inconsistency in results across studies.
RESULTS: We found 35 eligible studies, most of which were retrospective single-cohort studies. The final height SDS achieved by CAH patients was -1.38 (-1.56 to -1.20; I(2) = 90.2%), and the corrected height SDS was -1.03 (-1.20 to -0.86; I(2) = 63.1%). This was not significantly associated with age at diagnosis, gender, type and dose of steroid, and age of onset of puberty. Mineralocorticoid users had a better height outcome in comparison with the nonusers (P = 0.02).
CONCLUSION: Evidence derived from observational studies suggests that the final height of CAH patients treated with glucocorticoids is lower than the population norm and is lower than expected given parental height.

PMID 20823467  J Clin Endocrinol Metab. 2010 Sep;95(9):4161-72. doi: 10.1210/jc.2009-2616.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから